Evolocumab - novel options in the treatment of hyperlipidemia

Abstract

Evolocumab belongs to the monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors) which can further lower low density lipoprotein-cholesterol (LDL-C) by cca 60% in statin-treated patients.

Keywords

• cholesterol
• drug therapy
• LDL-cholesterol metabolism